These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23011220)

  • 21. A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment.
    Kim SE; Woo S; Kim SW; Chin J; Kim HJ; Lee BI; Park J; Park KW; Kang DY; Noh Y; Ye BS; Yoo HS; Lee JS; Kim Y; Kim SJ; Cho SH; Na DL; Lockhart SN; Jang H; Seo SW
    J Alzheimers Dis; 2018; 66(2):681-691. PubMed ID: 30320571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
    J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved.
    Hanseeuw B; Dricot L; Lhommel R; Quenon L; Ivanoiu A
    J Alzheimers Dis; 2016 May; 53(2):651-60. PubMed ID: 27232217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment.
    Kang SH; Cheon BK; Kim JS; Jang H; Kim HJ; Park KW; Noh Y; Lee JS; Ye BS; Na DL; Lee H; Seo SW
    J Alzheimers Dis; 2021; 80(1):143-157. PubMed ID: 33523003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of brain perfusion SPECT using an easy Z-score imaging system in the mild cognitive impairment subjects with brain amyloid-β deposition.
    Takemaru M; Kimura N; Abe Y; Goto M; Matsubara E
    Clin Neurol Neurosurg; 2017 Sep; 160():111-115. PubMed ID: 28715708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
    Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
    Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kwon M; Kim JS; Kim BJ; Lee JH
    Eur J Neurol; 2021 May; 28(5):1520-1527. PubMed ID: 33559375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
    Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
    Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI.
    Harrington KD; Lim YY; Ellis KA; Copolov C; Darby D; Weinborn M; Ames D; Martins RN; Savage G; Szoeke C; Rowe C; Villemagne VL; Masters CL; Maruff P
    Int Psychogeriatr; 2013 Oct; 25(10):1667-77. PubMed ID: 23866942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between white matter lesions and cerebral Aβ burden.
    Yi HA; Won KS; Chang HW; Kim HW
    PLoS One; 2018; 13(9):e0204313. PubMed ID: 30248123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.